NVNO enVVeno Medical Corp

Nasdaq Surgical & Medical Instruments & Apparatus DE CIK: 0001661053
AI RATING
SELL
78% Confidence

Investment Thesis

enVVeno shows exceptional revenue growth (+747% YoY) with positive gross margins indicating product-market validation, but operates in an unsustainable cash burn environment with less than one year of runway at current burn rates (-$3.2M operating cash flow against $2.6M cash). The company remains far from profitability with -$3.8M net loss despite improving YoY, necessitating near-term capital raise or dramatic revenue acceleration to survive.

Strengths

  • + Exceptional revenue growth of 747.4% YoY demonstrates strong commercial traction
  • + Positive gross margin (19.4%) indicates viable unit economics and product value
  • + Pristine balance sheet with zero long-term debt and minimal liabilities ($2.4M)
  • + Improving loss metrics year-over-year (net loss improved 10.8%, EPS improved 25.8%)
  • + Exceptional liquidity position (11.89x current ratio) relative to liabilities

Risks

  • ! Critical cash runway: Operating burn of $3.2M against cash reserves of only $2.6M suggests less than one year of operations
  • ! Revenue base remains microscopic at $161K, insufficient to support operating expense structure
  • ! Extreme operating losses (-$4.1M) and negative ROE/ROA indicate fundamental business model imbalance
  • ! Company dependent on capital raise or dramatic revenue acceleration for survival
  • ! Early-stage commercialization risk with limited commercial history

Key Metrics to Watch

Financial Metrics

Revenue
161.0K
Net Income
-3.8M
EPS (Diluted)
$-5.89
Free Cash Flow
-3.2M
Total Assets
26.1M
Cash
2.6M

Profitability Ratios

Gross Margin 19.4%
Operating Margin -2,523.0%
Net Margin -2,390.7%
ROE -16.2%
ROA -14.7%
FCF Margin -2,014.3%

Balance Sheet & Liquidity

Current Ratio
11.89x
Quick Ratio
11.89x
Debt/Equity
0.00x
Debt/Assets
9.0%
Interest Coverage
-13.30x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-07T07:09:44.167149 | Data as of: 2026-03-31 | Powered by Claude AI